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Summary
Digital health encompasses a wide range of novel digital
technologies related to health and medicine. Such tech-
nologies rely on recent advances in the collection and
analysis of ever increasing amounts of data from both
patients and healthy citizens. Along with new opportuni-
ties, however, come new ethical and policy challenges.
These range from the need to adapt current evidence-
based standards, to issues of privacy, oversight, account-
ability and public trust as well as national and international
data governance and management. This review illustrates
key issues and challenges facing the rapidly unfolding dig-
ital health paradigm and reflects on the impact of big data
in medical research and clinical practice both internation-
ally and in Switzerland. It concludes by emphasising five
conditions that will be crucial to fulfil in order to foster in-
novation and fair benefit sharing in digital health.
Keywords: digital health, personalised health, digital
ethics, data governance
Introduction
Digital health is a rapidly expanding medical field
premised on the availability of ever increasing amounts of
data about people’s lifestyles, habits, clinical histories and
pathophysiological characteristics. According to the US
Food and Drugs Administration (FDA) “[t]he broad scope
of digital health includes categories such as mobile health
(mHealth), health information technology (IT), wearable
devices, telehealth and telemedicine, and personalized
medicine” [1]. These categories rely heavily on human
health data. Conventionally, the collection of health data
is mediated by officially licensed medical devices, such
as diagnostic instruments or genome sequencers, operated
by health professionals in clinical environments and under
strict regulatory conditions. Moreover, clinical data are
typically stored in public health registries, at hospitals or
in the archives of individual physicians. Digital health, in
turn, entails connecting health-related data, including da-
ta generated by patients themselves, and harnessing the
medical potential of technological tools of common usage,
such as smartphones, wellness bands, apps, social media
and sensing devices disseminated in our dwelling environ-
ment. Most of these tools are not initially conceived for
medical use and are not marketed as medical devices. No-
tably, however, some prominent digital health technologies
already cut across the rigid distinction between licensed
and ordinary gadgets, and the latter have also started to re-
ceive official designation as medical devices (see table 1)
[16]. But digital health is not limited to ordinary technol-
ogy, nor to ordinary-turned-medical technologies. Certain
digital health tools present entirely novel features, as in the
case of digital pills that, thanks to a microcircuit activated
upon contact with liquids in the patient’s stomach, can tell
an external sensor whether and when a patient has taken
his or her medication.
The defining feature of digital health, however, has to do
with data rather than technology. What is distinctive about
digital health in this respect, is that – typically through
wearable, portable, ingestible or otherwise implantable de-
vices – it generates a “seamless flow of critical medical
data between patients, their families and their physicians”
[17]. The ambition of digital health is therefore aptly de-
scribed as generating a circulation of data from patients
(patient-generated data), to devices and/or health profes-
sionals (who analyse and make sense of the data), and then
back to devices that eventually provide the patient with in-
formation regarding their health status and how to manage
it.
To this aim, phenotypic and behavioural information, as
well as data about socioeconomic status and dwelling envi-
ronment, need to be collected. Information posted on social
media can also turn out to be potentially relevant to both
individual and population health [18, 19]. Digital health
thus inhabits what has been recently labelled an “evolving
health data ecosystem“ [20], a space that also includes data
gathered by healthcare services, such as electronic health
records, genetic or genomic data, diagnostic data, claims
data and the like. According to some, given their volume,
complexity, variety and propensity to be analysed through
data-mining techniques, such data qualify as big data [21]
or, more precisely, as biomedical big data [22–24]. This ex-
panded set of health-relevant data is expected to occasion
huge progress in medicine, for example by helping peo-
ple monitor their health status, assisting patients in cop-
ing with their conditions, inferring health-related issues
earlier on, personalising treatment to individual patients’
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characteristics, improving outcomes, reducing costs and
inefficiencies, and also boosting medical discovery and ac-
celerating drug development. Admittedly, there are signif-
icant expectations of digital health and there is strong in-
terest on the part of numerous stakeholders in promoting it
and seeing it flourish. At the same time, for digital health
to materialise several ethical and policy challenges need to
be overcome [25].
To review these challenges, a multidisciplinary symposium
was held at the University of Zurich (UZH) on 1 December
2016. The symposium, convened by UZH’s Health Ethics
and Policy Lab (now based at ETH Zurich), brought to-
gether different perspectives from national and internation-
al experts regarding the challenges that accompany the
development of digital health. Participants included scien-
tists, ethicists and lawyers, representative of national re-
search institutions such as the SAMS (Swiss Academy of
Medical Sciences) and the SNSF (Swiss National Science
Foundation), as well as policy specialists from interna-
tional organizations such as the OECD (Organization for
Economic Co-operation and Development) and the WHO
(World Health Organization).
Three key challenges impinging on the development of
digital health were identified and discussed:
1. How does digital health fare with respect to the de-
mands of evidence-based medicine?
2. How can public trust in digital health be generated and
sustained
3. What policy gaps can and should be addressed through
global policy instruments and what instead require
specific initiative in the Swiss context?
Here, we provide key considerations on the above three
questions, based both on the discussions held at the sym-
posium and further literature review. These considerations
are of relevance to scientists, ethicists and public health ex-
perts, as well as developers and policy makers interested
in assessing the impact of big data in medical research and
clinical practice, both internationally and in Switzerland.
Digital health and the quest for evidence
The clinical development of digital health applications is
premised on the creation of very large data collections
recording sensitive personal data. In the public sector, ex-
amples include: the 100K genomes cohort in the UK,
which aims to sequence the genome of one hundred thou-
sand NHS cancer patients by 2017; the All of Us cohort
of the Precision Medicine Initiative in the US, which will
collect samples, and phenotypic and clinical data from one
million Americans; or the Million Veteran Program, which
currently constitutes the largest genomic database in the
world and also includes lifestyle information and access to
electronic health records for research purposes [26]. Be-
sides these large-scale public initiatives, the private sector
is also collecting huge amounts of phenotypic and genet-
ic data from users of health-related services and products.
For example, as of June 2015, the genetic testing compa-
Table 1: Examples of licensed and unlicensed digital health technologies.
Company Product Type Year of license Licensing body Description
Licensed
AdhereTech, Inc. Smart Pill Bottle [2] Wireless pill bottle FDA, CE, ISO Smart wireless pill bottle capable
of alerting patients to missed dos-
es.
Airstrip Technologies AirStrip ONE® [3, 4] Mobile app 2014 FDA Provides an interoperable platform
that simplifies clinicians’ and pa-
tients’ access to diverse health da-
ta.
AliveCor, Inc. Kardia Mobile [5, 6] Wireless pad 2016 FDA Portable electrocardiogram device
displaying results on a smart-
phone. It can detect cardiac anom-
alies such as arrhythmia.
Blue Spark Technologies,
Inc.
TempTraq® [7, 8] Disposable patch Blue Spark Technologies,
Inc.
TempTraq® [7, 8] Disposable patch
Natural Cycles Natural Cycles [9] Wireless thermometer 2017 CE, ISO App to keep track of ovulation and
period, associated with a smart
thermometer to determine fertile
days. It can be used as a contra-
ceptive.
Proteus Digital Health Proteus Discover [10, 11] Ingestible sensor, wear-
able sensor and mobile
app
2014 FDA An ingestible sensor mounted on a
pill, which, when swallowed, sends
a signal to devices keeping track
of compliance with prescriptions.
Not licensed
Butterfly Network, Inc [12]. Compact ultrasound Portable ultrasound machines
trained through deep learning al-
gorithms.
Fitbit, Inc. Fitbit Aria™ [13] Wi-Fi smart scale Used in conjunction with an app, it
tracks body mass index, weight,
body fat percentage and lean
mass.
Happify, Inc. Happify™ [14] Mental health app Smartphone app aimed at alleviat-
ing stress and negative thoughts
through techniques in the form of
games and exercises.
MyFitnessPal, Inc. MyFitnessPal [15] Calorie counter app Free app to keep track of calorie
intake. It is said to help users who
want to lose weight.
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ny 23&Me had collected and genotyped DNA from more
than one million costumers [27]. In June 2016, the US-
based healthcare provider and insurer Kaiser Permanente
announced the constitution of a research biobank pulling
electronic health records, DNA and behavioural and envi-
ronmental information from 500 000 people [28]. Finally,
end-users of digital health devices such as heart monitoring
apps or fitness gadgets also contribute vast amounts of data
to service providers. Such data can be cross-linked to other
existing large-scale repositories both for research purposes
and for developing new digital health services to users and
professionals alike.
The evidence base for digital health
Mining large-scale data repositories creates challenges re-
garding data management, privacy protection and over-
sight mechanisms. Other challenges, however, relate more
directly to the composition of such repositories and to the
tools employed to mine the data they contain. For instance,
the use of convenience samples to populate precision med-
icine and precision public health cohorts can bias the sam-
ple compositions and compromise the representativeness
of target populations [29, 30]. Such issues can affect the
quality of the evidence derived from digital health research
and employed in digital health-based interventions, both
at the individual and at the population level. Taking into
account ethnicity, age, sex, socioeconomic status and ge-
ographical distribution in recruiting research participants
thus seems crucial to ensure the generalisability of research
findings. Similarly, the representativeness of the datasets
employed for product development and the robustness of
analytic tools to mine such datasets can affect the devel-
opment of effective digital health services and devices by
private companies.
There seems to be room for precompetitive research in
this area in order to at least create standards and possibly
reference datasets to enhance reproducibility. Meanwhile,
progress in regulatory science should enable better assess-
ments of evidence for safety, efficacy and cost-effective-
ness. In both cases, policy stimulus appears crucial to
achieve tangible results. As for more user-oriented digital
health applications, as with products and services devel-
oped outside the realm of licensed devices, there is the
need to enhance transparency and accountability by adopt-
ing forms of sector-specific self-regulation and adhering to
robust corporate responsibility schemes.
Data variety is also a key issue in digital health. For exam-
ple, although genetics can be extremely informative from
a medical point of view, with a few notable exceptions the
contribution of genetic variation to most common chronic
conditions is either unknown or relatively small. Instead,
other types of information, such as levels of physical ac-
tivity, diet and socioeconomic factors, are better suited for
predicting the risk of developing a chronic disease [31].
Therefore, to harness the full potential of data mining and
predictive analytics in digital health, genomic data alone
are insufficient [32, 33].
Novel modes of evidence generation could take into ac-
count multidimensional and unstructured data along with
conventional clinical measures. For example, in health out-
comes research or assessment of long-term effects of drugs
and interventions, pragmatic trial designs are raising con-
siderable interest. Such studies employ less restrictive in-
clusion criteria than traditional clinical trials and allow for
concomitant morbidities and medications. Such models re-
ly on “real-world data” collected from actual patients [34]
– data that would simply not be available in randomised
controlled trials. Real world data include medical records,
data from portable devices and social media, as well as
environmental and socioeconomic data. Other than saving
on the high costs of randomised controlled trials, prag-
matic trials based on reals world data promise to be more
representative of real populations. At least when risks are
deemed reasonably low, real-world evidence obtained
through pragmatic designs could thus be used in support of
regulatory decisions about the safety and efficacy of dig-
ital health devices and applications. Moreover, real-world
evidence could also be employed to retrospectively assess
digital health applications that reached the market without
being cleared by regulatory agencies.
The technologies that are enabling extensive data collec-
tion and the development of digital health can be applied
to both individual and population health issues, contribut-
ing to the emerging fields of precision medicine and pre-
cision public health, respectively [35–38]. Both the former
and the latter promise more tailored interventions in their
respective domains, progress in the understanding of dis-
ease causes and outcomes, along with reduced costs and
improved access to effective healthcare. Both precision
medicine and precision public health have specific sets of
ethical implications [39, 40]. In such areas, larger, more
representative and diverse databases are expected to tackle
very well-known issues of external validity that afflict ran-
domized controlled trials [41, 42]. Yet this prospect is af-
fected by the challenges discussed above. Moreover, the
use of artificial intelligence (AI) and deep learning [43]
to mine such large data repositories has led many to think
that digital health can dispense with mechanistic explana-
tions and hypothesis-driven research, replacing them with
mere algorithm-guided searches for correlations between
phenomena in large-scale observational studies [44–47]. It
has been noted, however, that even if those methods prove
effective in establishing robust correlations, controlled in-
terventional, randomised trials on stratified patient cohorts
will still be necessary to establish the safety and clinical
utility of novel therapies or public health interventions
[48].
Ethical and policy challenges in digital health
Privacy and security
Most of the debate about big data uses for health purposes
has focused on privacy. As more data sources become
available and advanced analytics can be applied for various
purposes, protecting privacy is undoubtedly a complex
challenge. What contributes to this complexity is that stan-
dard mechanisms of protection such as anonymisation, no-
tice and consent are excessively stretched in this environ-
ment of new capabilities. Consent for data uses can hardly
include the exhaustive list of all possible future data us-
es [49]. In turn, anonymisation technologies, even if ro-
bust, still leave re-identification in the realm of possibility
if enough resources were to be devoted to it. Data securi-
ty has also been a challenge, with cyber attacks, hacking
of databases and data kidnapping being reported frequent-
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ly. Incidents of data breaches and “kidnapping” (data held
by hackers for ransom) are on the rise. According to the
Breach Portal of the Health and Human Services (HHS)
Office of Civil Rights, millions of healthcare records have
been affected to date. In May 2017, healthcare databases in
one hundred countries faced a ransomware attack claiming
a ransom of $300 in bitcoin to unlock affected machines
[50]. The UK’s Information Commissioner’s Office notes
that the health sector accounts for most of the data inci-
dents reported to them. These incidents, along with grow-
ing public concerns about big data affecting most aspects
of contemporary life, have contributed to a bleak picture of
the future of privacy [51]. Understandably, such a picture
does not create an environment conducive to the demands
of digital health, namely easier data circulation between
individuals, devices and institutions. Against this back-
ground, the public needs to be reassured that robust secu-
rity measures are mandated and enforced through clearly
articulated policies. Concerns can be addressed with the
adoption of appropriate technologies, monitoring and eval-
uation of security systems, transparency and accountabil-
ity mechanisms such as legal remedies and compensation
for privacy harms resulting from security breaches. Secu-
rity will continue to evolve, but the big data approach will
continue to demand more technical skills, responsive poli-
cies and regulatory oversight.
Trust
Essentially what is at stake is the creation of a culture
of trust that will enable all stakeholders in the big data
ecosystem to benefit from the development of digital
health [52]. In particular, public trust in health data uses is
of paramount importance. The recent case of the care.da-
ta in the UK serves as a good example of how mistrust on
the part of the public can derail large-scale data initiatives
(see table 2). But trustworthy digital health activities re-
quire more than privacy protection. Elements of trust in-
clude transparency, accountability, benefit sharing and cer-
tainly more clarity about data ownership and data control.
What is important here is the realisation that trust cannot
only be built through achieving just one element, but rather
through a concerted effort to promote all of its elements.
Therefore, trustworthiness cannot merely be achieved by
innovative consent models offering more or less control
of data uses. Rather, consent innovation has to also be ac-
companied by clarity on how individuals and communities
will benefit from digital health developments, by oversight
mechanisms that protect common interests and by account-
ability mechanisms that can sustain public scrutiny.
Accountability
With automated data mining for decisions of clinical or
public health relevance becoming one of the most promis-
ing features of digital health, accountability is of critical
importance. In particular, the adoption of these new tools
requires relevant adaptations in existing accountability
standards. For instance, in the field of digital epidemiolo-
gy, data mining can be used to analyse free, unstructured
text from social networks in order to make predictions
about the spread of infectious diseases [34]. Moreover, mo-
bile technologies can be used to target specific popula-
tions with health-related information that can help contain
the spread of infectious diseases. These new approaches
can increase the speed and accuracy of health dynam-
ics monitoring, leading to more targeted and effective in-
terventions. However, premature reliance on such innov-
ative tools could lead to an inappropriate use of public
resources, unnecessary public alarm and individual harm
from dispensable medications [55]. Similarly, it is antici-
pated that medical practice will increasingly be aided by
AI algorithms for diagnosis, treatment decisions and sur-
gical procedures [55, 56]. Progress in such areas is ex-
pected to greatly improve the quality of healthcare pro-
vision for individual patients. Such tools can range from
simply providing assistance to practitioners, to possibly
one day being fully autonomous from human supervision
[57]. Indeed, increasing sophistication could lead to more
accuracy. However, as more AI-guided tools become au-
tonomous, fewer human operators are able to override their
decisions. Hence, AI-guided medical devices have the po-
tential to jeopardise current norms of professional account-
ability in clinical practice, making it more complicated to
trace responsibility back to individual practitioners. It is
therefore crucial that ad hoc, robust evidence standards are
elaborated to guide the adoption of digital health technolo-
gies in clinical practice [58, 59].
Governance approaches in the development of
digital health
Global perspective
The strong technological component of digital health does
not imply that innovation in this area will affect only the
most affluent countries. Recent figures published by the
Global Observatory on eHealth of the WHO show that
health systems in most countries increasingly rely on data
[60]. In fact, the decreasing cost of digital technologies is
making it possible also for low- and middle-income coun-
tries to adopt telehealth, mHealth, eLearning, electronic
health records and big data. EHealth initiatives are under-
way in 83% of WHO Member States, and 90% of them
Table 2: Case study overview: care.data National Health Service (NHS) England [53, 54].
NHS launched care.data in 2013 as an initiative to collect and store patient data from GPs (general practitioners) around the country in the Health and Social Care Information
Centre database (HSCIC; now NHS Digital).
HSCIS already collected hospital data. Analysing GPs data as well was supposed to improve outcomes and customer service, as well as to further understanding of diseases
and treatments.
Despite initial endorsement by various professional societies, strong public reactions against the initiative were triggered by concerns about privacy, lack of transparency re-
garding data access and the involvement of commercial entities.
Reports by the National Data Guardian and the Care Quality Commission that highlighted that inadequacies in transparency and privacy led to the discontinuation of care.data.
The reports emphasised that citizens should be able to exercise their “right to know how their data are safeguarded. They should be included in conversations about the poten-
tial benefits that responsible use of their information can bring. They must be offered a clear choice about whether they want to allow their information to be part of this.”
Lessons learned: in order to build public trust in the use of health and care data, initiatives need to meet criteria of trustworthiness, transparency, open communication and a
clear sense of the distribution of benefits.
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have an eHealth strategy. Different forms of digital health
and digital health technology, however, present different
patterns of global distribution, with telemedicine being
more widely spread than electronic health records, which
are more commonly used than big data in healthcare set-
tings. Therefore, despite the fact that digital health repre-
sents a global phenomenon, it is adopted and implemented
differently across the globe.
Not surprisingly, from a global perspective the governance
of health data appears patchy, with only about half of
WHO countries having specific privacy protections in
place for personal health data. Robust national data gover-
nance frameworks tailored to the needs of real populations
are thus considered a precondition for digital health to de-
liver sustained health benefits and to meet global health
objectives such as universal health coverage. In addition,
the development of international interoperability standards
should continue in order to improve the capacity to mon-
itor health needs and to deliver more effective interven-
tions.
International policy organisations have addressed data
governance issues for digital health from a global perspec-
tive. The OECD, for instance, has published a set of rec-
ommendations for health data governance [61]. Besides
endorsing the idea that better health information systems
and more efficient data use can improve healthcare provi-
sion, the OECD focuses on ways to maximise the usabili-
ty of data for public policy, ensuring that health data pro-
cessing serves the public interest, and secures public trust
in data-driven health systems. To this aim, the OECD high-
lights several areas of intervention, including: promoting
public engagement of a wide array of stakeholders; fos-
tering collaboration to enhance interoperability and data
sharing; providing clear information to individual data sub-
jects; ensuring appropriate informed consent procedures;
pursuing accurate review of data access and data process-
ing requests; promoting transparency through public infor-
mation about data use; and adopting effective control and
safeguard mechanisms to protect personal data.
At the European level, the recently promulgated General
Data Protection Regulation [62], which replaced the Data
Protection Directive of 1995, aims at creating a more ho-
mogeneous legal framework in European Union Member
States for the governance of personal data, including per-
sonal health data. This new framework stresses the impor-
tance of explicit consent to data processing, but recognises
that explicit consent is not always possible in the domain
of scientific research, in which data originally collected for
one project are likely to be re-used by multiple researchers
for purposes unrelated to the initial one. The GDPR also
recognises that data processing can take place without con-
sent if there is a pressing public health need to be ad-
Figure 1: Conditions of innovation in digital health. This graph describes the conditions for innovation in digital health, for both licensed
and non-licensed products and applications. Along the continuum from data generation to health impact, several conditions need to be fulfilled
for digital health applications to have a tangible effect on individual and public health. To begin with, sufficient amounts of health data about in-
dividuals, as well as other types of data helpful to the detection, treatment and monitoring of health conditions in peoples and populations,
need to be accessible to developers. Secondly, digital health products need to comply with data protection and privacy requirements in the
countries in which they operate. Third, accountability mechanisms should be in place to trace responsibility for data uses and their conse-
quences on individuals, families and communities. Accountability also ensures transparent communication of health relevant information to da-
ta subjects. Fourth, solid evidence of safety and efficacy should back medical claims of digital health products. More rigidly enforced eviden-
tiary standards – including cost-effectiveness requirements – will foreseeably apply to digital health products seeking license from national
regulatory agencies (such as the FDA or EMA). Yet, also non-licensed products can and should have sufficient evidentiary bases. Only the ful-
filment of all such conditions creates trust in developers and regulators of digital health products and is conducive to fair benefit sharing of digi-
tal health innovation.
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dressed. Similarly, certain informational rights such as the
right to have one’s data erased can be limited in the name
of public health emergencies, while certain sensitive data
– like genetic data, for instance – can enjoy special pro-
tections set by individual member states. At any rate, the
governance of data processing for research purposes and
the processing of data from health registries remain sub-
ject to national rules. In terms of governance, the GDPR
puts the burden of demonstrating compliance with its pro-
visions entirely on the shoulders of data controllers, thus
considerably raising the bar of accountability demands in
comparison with the previous data protection directive.
Governance should enable digital health innovation to ad-
dress the challenges discussed above, which include not
only accountability but also privacy, quality of evidence,
data access and sharing, and ultimately trust. Essentially,
these are five key conditions that can determine whether
digital health innovation can lead to health benefit (fig. 1).
It remains to be seen whether, and how, a global gover-
nance approach can achieve this. For any approach it will
be crucial to ensure that all stakeholders are involved and
engaged. In this respect, the emphasis that the WHO puts
on public participation and engagement of broad arrays of
stakeholders aptly recognises the need to ensure that digi-
tal health serves the public interest and facilitates patients’
engagement in health-related decisions.
The Swiss context
The development of digital health faces similar challenges
in most developed countries. However, individual coun-
tries face these challenges to different degrees depending
on the quality of their IT infrastructure, regulatory frame-
works, healthcare systems and so on. Currently, a number
of significant developments mark a turning point for digital
health in Switzerland. First, the enactment of the Swiss
electronic patient dossier legislation [63], on 15 April
2017, is an important step toward further digitalisation in
the country’s healthcare sector. The dossier, a voluntary
electronic collection of personal medical documents, is de-
signed to provide healthcare professionals with easier ac-
cess to patient information, thus improving the safety and
accuracy of diagnosis, with the ultimate goal of a posi-
tive impact on patient treatment and care. Whereas some
Swiss regions have already put digital patient dossiers in
place (see for instance the Geneva health information ex-
change e-toile [64], or the project dossier patient partagé -
Infomed in the canton of Valais [65]), no provider has been
officially certified to date, and both the legal and organi-
sational prerequisites are being gradually implemented this
year with a view to have the system running by mid-2018.
Even though Switzerland benefited from the insights of
major ongoing eHealth projects in Europe [66], the process
towards more centralisation of national digital health pol-
icy-making has been slow and non-linear [67, 68]. Never-
theless, the electronic patient dossier has overcome various
political and organisational hurdles and can help advance
other digital health services and initiatives, such as the
cross-border harmonisation of e-medication records [69].
One crucial factor for the development of digital health is
data accessibility. Ideally, data should be made available
for further research uses that promise progress in individ-
ual or population health, and research and clinical institu-
tions should be willing to open up their patients’ data for
that aim. Despite repeated appeals on the importance of da-
ta access, however, this practice is still implemented to an
insufficient degree. Some barriers to data sharing are more
regulatory in nature, such as the inability of data subjects to
truly consent to uses that are not foreseeable at the moment
of data collection. Some others are more organisational, as
in the case of institutions that are reluctant to share data for
liability issues. Currently existing patient data are collected
through diverse technological systems and with variations
in the consent that authorises further uses.
The second important development in Switzerland aims to
address this issue through the proposal of a national broad
consent template. Spearheaded by the Swiss Academy of
Medical Sciences, a so-called “general consent” has been
developed after extensive consultation with various stake-
holders. The aim of this broad consent is to harmonise the
conditions under which further data uses can take place.
The model of broad consent has been highly debated in
the bioethics literature, however, and commentaries range
from full approval to complete rejection [70–73]. Broad
consent may not be the ultimate solution to conducting
ethical secondary uses of data. However, if accompanied
by robust oversight and accountability systems it can be a
pragmatic solution that facilitates ethical digital health re-
search [74].
The third relevant development in Switzerland is the
launch of the Swiss Personalized Health Network (SPHN)
[75] – a national initiative designed to build the necessary
infrastructure to improve the utilisation of health-related
data for research and innovation. The development of dig-
ital health, as that of other data-driven activities, depends
on the development of appropriate technical standards to
make data securely exchangeable and efficiently com-
putable. Accordingly, the SPHN aims to develop interop-
erability standards that will enhance data accessibility for
research uses in Switzerland. The SPHN’s vision on data
governance is based on an ethics framework including four
principles: respect for persons, data fairness, privacy, and
accountability. Such a soft law instrument, while indicat-
ing the direction for improving data sharing, is also flexi-
ble enough to adapt to stakeholders’ organisational needs.
Public engagement
Citizens and patients are increasingly becoming the driving
forces behind digital health developments [76, 77]. The ex-
tensive adoption and sustainability of health data exchange
thus depend upon information technology that facilitates
patient engagement and the earning of public trust [78]. To
build on the support of the public, it should be made clear
that digital health is a tool for citizens and professionals
alike [79–81]. This is a condition for fostering trust around
digital health [82]. Furthermore, public policy needs take
into account the digital divide and the capacity of citizens
to engage with e-health [83–86]. And whereas it is certain-
ly important to promote collaboration among healthcare
professionals and institutions, other agents, such as start-
ups and the industry in general, ought to be included in the
country’s digital health transformation with mechanisms
to incentivise partnership, investments and data sharing
[87–89]. This can take the form of public/private partner-
ships [90], such as the Digital Switzerland Initiative [91]
and the Opendata.ch Foundation [92].
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Other innovative models to leverage private initiatives and
foster public engagement are emerging. In Switzerland, the
MIDATA cooperative is a case in point [93]. MIDATA of-
fers data subjects the possibility of storing health data from
different sources and leaves it to the data subjects to decide
collectively on data access requests [94, 95]. All data con-
tributors are equal shareholders of the cooperative, which
is a not-for-profit entity and will re-invest any potential in-
come generated by granting access to its data. This unique
model is already active in digital health-related projects in
Switzerland and will promote the inclusion of patient-gen-
erated data that are needed to develop digital health into
clinical applications.
Conclusion
Innovation in digital health faces several ethical and policy
challenges. We have argued that, for digital health products
and applications to produce tangible innovation and health
impacts, be it at the individual or at the population level,
five conditions need to be met. First, data are of paramount
importance for digital health: access to sufficient amounts
of data is thus a primary condition for the development of
innovative diagnostic, therapeutic and monitoring tools is
this area. Second, alignment with existing legal provisions
regarding data protection, data security and privacy are key
to digital health innovation. Legal frameworks can thus
have a major impact in facilitating or hindering progress in
this field. Nonetheless, legal provisions do not address the
full range of ethical issues in data processing. Nor do they
cover the full spectrum of legitimate concerns of data sub-
jects. Third, robust and transparent accountability mecha-
nisms should ensure the precise identification of responsi-
bility for data uses and their consequences on individuals,
families and communities. What is more, accountability
also sets up mechanisms for communicating health rele-
vant information to data subjects. Fourth, evidence of safe-
ty and efficacy is a significant condition for the success
of digital health. Licensed digital health products and ap-
plications will have to go through extensive assessment
processes and will have to meet cost-effectiveness require-
ment before they can be reimbursed by insurers and public
healthcare systems. This does not, however, mean that un-
licensed products and applications can lack some form of
evidence to back up their claims. Fulfilling these require-
ments will foster the fifth condition for digital health in-
novation, that is, trust in both developers and regulators,
which in turn will facilitate the uptake of digital health by
healthcare providers and lead to fair benefit sharing of dig-
ital health innovation.
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